MiMedx Operating Cycle from 2010 to 2026

MDXG Stock  USD 5.17  0.03  0.58%   
MiMedx's Operating Cycle is decreasing over the last several years with very volatile swings. Operating Cycle is predicted to flatten to 209.80. During the period from 2010 to 2026 MiMedx Group Operating Cycle regressed destribution of quarterly values had coefficient of variationof  32.72 and r-value of (0.08). View All Fundamentals
 
Operating Cycle  
First Reported
2010-12-31
Previous Quarter
233.52
Current Value
209.8
Quarterly Volatility
63.60456735
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check MiMedx financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among MiMedx's main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.7 M, Interest Expense of 1.8 M or Selling General Administrative of 130 M, as well as many indicators such as Price To Sales Ratio of 4.43, Dividend Yield of 0.0 or PTB Ratio of 8.0. MiMedx financial statements analysis is a perfect complement when working with MiMedx Valuation or Volatility modules.
  
Build AI portfolio with MiMedx Stock
Check out the analysis of MiMedx Correlation against competitors.
The Operating Cycle trend for MiMedx Group offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether MiMedx is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.

Latest MiMedx's Operating Cycle Growth Pattern

Below is the plot of the Operating Cycle of MiMedx Group over the last few years. It is MiMedx's Operating Cycle historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in MiMedx's overall financial position and show how it may be relating to other accounts over time.
Operating Cycle10 Years Trend
Very volatile
   Operating Cycle   
       Timeline  

MiMedx Operating Cycle Regression Statistics

Arithmetic Mean194.37
Geometric Mean184.15
Coefficient Of Variation32.72
Mean Deviation51.31
Median201.60
Standard Deviation63.60
Sample Variance4,046
Range217
R-Value(0.08)
Mean Square Error4,289
R-Squared0.01
Significance0.77
Slope(0.98)
Total Sum of Squares64,729

MiMedx Operating Cycle History

2026 209.8
2025 233.52
2024 203.06
2023 201.6
2022 158.3
2021 165.76
2020 148.24

About MiMedx Financial Statements

MiMedx stakeholders use historical fundamental indicators, such as MiMedx's Operating Cycle, to determine how well the company is positioned to perform in the future. Although MiMedx investors may analyze each financial statement separately, they are all interrelated. For example, changes in MiMedx's assets and liabilities are reflected in the revenues and expenses on MiMedx's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in MiMedx Group. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Operating Cycle 233.52  209.80 

Currently Active Assets on Macroaxis

When determining whether MiMedx Group is a strong investment it is important to analyze MiMedx's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact MiMedx's future performance. For an informed investment choice regarding MiMedx Stock, refer to the following important reports:
Check out the analysis of MiMedx Correlation against competitors.
You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Can Biotechnology industry sustain growth momentum? Does MiMedx have expansion opportunities? Factors like these will boost the valuation of MiMedx. Expected growth trajectory for MiMedx significantly influences the price investors are willing to assign. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating MiMedx demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Quarterly Earnings Growth
1.138
Earnings Share
0.27
Revenue Per Share
2.668
Quarterly Revenue Growth
0.353
Return On Assets
0.1198
The market value of MiMedx Group is measured differently than its book value, which is the value of MiMedx that is recorded on the company's balance sheet. Investors also form their own opinion of MiMedx's value that differs from its market value or its book value, called intrinsic value, which is MiMedx's true underlying value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Because MiMedx's market value can be influenced by many factors that don't directly affect MiMedx's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that MiMedx's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether MiMedx represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, MiMedx's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.